Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

OBJECTIVE: TAS‐102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS‐102 improves clinical outcomes in refractory mCRC. PATIENTS AND METHODS: We retrospectively analyzed data from Japanese patients with re...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Hironori, Matsuhashi, Nobuhisa, Kitahora, Mika, Takahashi, Takao, Hirose, Chiemi, Iihara, Hirotoshi, Yamada, Yunami, Watanabe, Daichi, Ishihara, Takuma, Suzuki, Akio, Yoshida, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066722/
https://www.ncbi.nlm.nih.gov/pubmed/32162797
http://dx.doi.org/10.1634/theoncologist.2019-0541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066722/
https://www.ncbi.nlm.nih.gov/pubmed/32162797
http://dx.doi.org/10.1634/theoncologist.2019-0541

Ejemplares similares